15116-41-3

Usage

Uses

Used in Organic Synthesis:
(E)-N-(3-METHOXY-PHENYL)-3-PHENYL-ACRYLAMIDE is utilized as a building block in organic synthesis for the preparation of various organic compounds and pharmaceutical intermediates. Its unique structure allows for the creation of a wide range of molecules with potential applications in different fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (E)-N-(3-METHOXY-PHENYL)-3-PHENYL-ACRYLAMIDE is used as a starting material for the development of new drugs. Its structural features and potential biological activities make it a valuable component in the design and synthesis of pharmaceuticals with specific therapeutic targets.
Used in Drug Discovery:
(E)-N-(3-METHOXY-PHENYL)-3-PHENYL-ACRYLAMIDE also plays a role in drug discovery, where it can be employed to explore its potential as a lead compound for the treatment of various diseases. Its aromatic and double bond functional groups offer opportunities for further chemical modifications to enhance its pharmacological properties and effectiveness.

Upstream product

• 536-90-3 m-Anisidine 
• 621-82-9 Cinnamic acid 
• 102-92-1 cinnamoyl chloride 

Downstream Products

• 23981-26-2 7-methoxyquinolin-2(1H)-one 
• 49609-15-6 2-chloro-7-methoxyquinoline 
• 1354030-42-4 7-(4-(4-(2-isopropoxyphenyl)-1,4-diazepan-1-yl)butoxy)quinolin-2(1H)-one 
• 1354030-38-8 7-(3-(4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)propoxy)quinolin-2(1H)-one 
• 1076199-59-1 7–(3-bromopropoxy)quinolin-2(1H)-one 
• 1354030-37-7 7-(4-(4-(2-ethoxyphenyl)-1,4-diazepan-1-yl)butoxy)quinolin-2(1H)-one 
• 1354030-31-1 7-(4-(4-(2-methoxyphenyl)-1,4-diazepan-1-yl)butoxy)quinolin-2(1H)-one 
• 1354030-20-8 7-(4-(4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)butoxy)quinolin-2(1H)-one 
• 203395-59-9 7–(4-bromobutoxy)quinolin-2(1H)-one 
• 70500-72-0 7-hydroxy-1H-quinolin-2-one 

Relevant academic research and scientific papers

TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors

Four series of acid amides were synthesized, and through measurement using a fluorogenic substrate assay with human recombinant MMP-1, MMP-2 and MMP-9, compound 3f showed considerable inhibitory activities against MMP-2, MMP-9 and the best selectivity over MMP-1. Preliminary structure-activity relationship analysis indicated that caffeic acid amides with electron-donating groups at para-position of amino phenyl group showed better inhibitory activities and selectivity than those with electron-withdrawing groups, and the presence of adjacent dihydroxy in the caffeoyl group was very important for the MMP-2 and MMP-9 inhibitory activities.

FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS

The present invention relates to novel functionally selective ligands of dopamine D2 receptors, including agonists, antagonists, and inverse agonists. The invention further relates to the use of these compounds for treating central nervous system disorders related to D2 receptors.

Inhibitors of prenyl-protein transferase

The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase and the prenylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invent